Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors

Shengyi Wang; Xiaoyu Xu; Tapani Viitala; Yilai Shu; Hongbo Zhang

doi:10.1016/j.omtn.2025.102737

Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors

Shengyi Wang
, Xiaoyu Xu
, Tapani Viitala
, Yilai Shu
, Hongbo Zhang^*

^*Tämän työn vastaava kirjoittaja

Tutkimustuotos: Lehtiartikkeli › Katsausartikkeli › vertaisarvioitu

10 Sitaatiot (Scopus)

28 Lataukset (Pure)

Abstrakti

RNA forms of CRISPR-Cas9-based gene therapies provide more safer and effective therapeutic outcomes. This paper offers a reference for improving the effects of RNA forms of CRISPR-Cas9-based therapies, through the rational engineering design of mRNA components, combined with novel structural RNAs and novel delivery vehicles.

Alkuperäiskieli	Englanti
Artikkeli	102737
Julkaisu	Molecular Therapy Nucleic Acids
Vuosikerta	36
Numero	4
DOI - pysyväislinkit	https://doi.org/10.1016/j.omtn.2025.102737
Tila	Julkaistu - jouluk. 2025
OKM-julkaisutyyppi	A2 Katsausartikkeli tiedejulkaisuussa (artikkeli)

Pääsy asiakirjaan

10.1016/j.omtn.2025.102737Lisenssi: CC BY

PIIS2162253125002914Lopullinen julkaistu versio, 7,94 MBLisenssi: CC BY

https://urn.fi/URN:NBN:fi-fe20251205114798

Åbo Akademi Functional Printing Center
Toivakka, M. (PI), Rosenholm, J. (PI), Anttu, N. (PI), Bobacka, J. (PI), Huynh, T. P. (PI), Peltonen, J. (PI), Wang, X. (PI), Wilen, C.-E. (PI), Xu, C. (PI), Zhang, H. (PI) & Österbacka, R. (PI)
Luonnontieteiden ja tekniikan tiedekunta
Laitteistot/tilat: Laitos

MADNESS: Centre of Excellence in Materials-driven solutions for combatting antimicrobial resistance
Rosenholm, J. (Vastuullinen tutkija), Porres Paltor, I. (CoPI), Bansal, K. (Koordinaattori), Lafond, S. (CoPI), Uppstu, P. (CoPI), Viitala, T. (CoPI), Wang, X. (CoPI), Wilen, C.-E. (CoPI), Xu, C. (CoPI), Zhang, H. (CoPI), Lu, Z. (CoI), Verma, J. (CoI), Kumar, V. (CoI), Frejborg, F. (CoI), Wang, S. (CoI), Ran, M. (CoI), Ma, X. (CoI), Yang, W. (CoI), Liang, S. (CoI), Zhang, Y. (CoI), Fan, L. (CoI), Chen, Y. (CoI), Wang, L. (CoI), Zhuang, P. (CoI), Rajan Prakash, D. (CoI), Howaili, F. (CoI), Gulshan, R. (CoI), Yadav, D. (CoI), Pathak, C. (CoI), Mustafa, R. (CoI), DarzianRostami, L. (CoI), Jafari Dargahlou, M. (CoI), Nygård, A. (CoI), Samrat, S. R. (CoI), Rexha, H. (CoI), Shiralizadeh Dezfuli, A. (CoI), Rahman Samrat, S. (CoI), Kohoolat, G. (CoI), Rezaeipour, Y. (CoI), Yadav, D. (CoI), Xia, Q. (CoI), Jafari Dargahlou, M. (CoI), Yang, W. (CoI) & Bayandori, M. (CoI)
Åbo Akademin säätiö sr
01/01/24 → 31/12/28
Projekti: Foundation
PII: Printed Intelligence Infrastructure
Toivakka, M. (Vastuullinen tutkija), Xu, C. (CoPI), Bobacka, J. (CoPI), Viitala, T. (CoPI), Rosenholm, J. (CoPI), Österbacka, R. (CoPI), Anttu, N. (CoPI), Huynh, T. P. (CoPI), Peltonen, J. (CoPI), Wang, X. (CoPI), Zhang, H. (CoPI) & Wilen, C.-E. (CoPI)
Suomen Akatemia
01/01/24 → 31/12/28
Projekti: Research Council of Finland/Other Research Councils

Viittausmuodot

@article{b7f98b230cb14fcfade579852307e2a0,

title = "Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors",

abstract = "RNA forms of CRISPR-Cas9-based gene therapies provide more safer and effective therapeutic outcomes. This paper offers a reference for improving the effects of RNA forms of CRISPR-Cas9-based therapies, through the rational engineering design of mRNA components, combined with novel structural RNAs and novel delivery vehicles.",

author = "Shengyi Wang and Xiaoyu Xu and Tapani Viitala and Yilai Shu and Hongbo Zhang",

year = "2025",

month = dec,

doi = "10.1016/j.omtn.2025.102737",

language = "English",

volume = "36",

journal = "Molecular Therapy Nucleic Acids",

issn = "2162-2531",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors

AU - Wang, Shengyi

AU - Xu, Xiaoyu

AU - Viitala, Tapani

AU - Shu, Yilai

AU - Zhang, Hongbo

PY - 2025/12

Y1 - 2025/12

N2 - RNA forms of CRISPR-Cas9-based gene therapies provide more safer and effective therapeutic outcomes. This paper offers a reference for improving the effects of RNA forms of CRISPR-Cas9-based therapies, through the rational engineering design of mRNA components, combined with novel structural RNAs and novel delivery vehicles.

AB - RNA forms of CRISPR-Cas9-based gene therapies provide more safer and effective therapeutic outcomes. This paper offers a reference for improving the effects of RNA forms of CRISPR-Cas9-based therapies, through the rational engineering design of mRNA components, combined with novel structural RNAs and novel delivery vehicles.

U2 - 10.1016/j.omtn.2025.102737

DO - 10.1016/j.omtn.2025.102737

M3 - Review Article or Literature Review

SN - 2162-2531

VL - 36

JO - Molecular Therapy Nucleic Acids

JF - Molecular Therapy Nucleic Acids

IS - 4

M1 - 102737

ER -

Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors

Abstrakti

Pääsy asiakirjaan

Sormenjälki

Laitteet

Åbo Akademi Functional Printing Center

Projektit

MADNESS: Centre of Excellence in Materials-driven solutions for combatting antimicrobial resistance

PII: Printed Intelligence Infrastructure

Viittausmuodot